Nimodipinum [Inn-Latin]

• Antihypertensive Agents
• Vasodilator Agents
• ATC:C08CA06

• Nimodipine [Usan:Ban:Inn]
• Nimodipino [Inn-Spanish]
• Nimodipinum [Inn-Latin]
• Nimotop
• Periplum

• No information avaliable

C₂₁H₂₆N₂O₇

http://www.rxlist.com/cgi/generic2/nimodip.htm

Nimodipinum_[Inn-Latin] FDA

No information avaliable

418.44 g/mol

No information avaliable

No information avaliable

Solid

3.152

Capsules

For the treatment of subarachnoid bleeding.

Nimodipine belongs to the class of pharmacological agents known as calcium channel blockers. Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured congenital aneurysms who are in good neurological condition post-ictus (e.g., Hunt and Hess Grades I-III). The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarization as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. In animal experiments, nimodipine had a greater effect on cerebral arteries than on arteries elsewhere in the body perhaps because it is highly lipophilic, allowing it to cross the blood brain barrier.

No information avaliable

No information avaliable

No information avaliable

Humans and other mammals